Royalty Pharma (RPRX.US): The 2024 Q1 financial report achieved revenue of US$568 million, with a previous value of US$684 million, with an expected value of US$663.2 million; earnings per share were US$0.98, the previous value was US$1.60, and the expected value was US$0.99.
Royalty Pharma(RPRX.US)：2024年Q1财报实现营收5.68亿美元，前值为6.84亿美元，预期值为6.632亿美元；每股收益为0.98美元，前值为1.60美元，预期值为0.99美元。
Royalty Pharma (RPRX.US): The 2024 Q1 financial report achieved revenue of US$568 million, with a previous value of US$684 million, with an expected value of US$663.2 million; earnings per share were US$0.98, the previous value was US$1.60, and the expect
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.